Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
Stock Information for Lyra Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.